JRCT ID: jRCT2080224558
Registered date:05/02/2019
Basic Information
Recruitment status | terminated |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 01/03/2019 |
Target sample size | 27 |
Countries of recruitment | Japan |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : macitentan Therapeutic category code : 219 Other cardiovascular agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material : |
Outcome(s)
Primary Outcome | efficacy |
---|---|
Secondary Outcome | safety efficacy |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | <= 89age old |
Gender | Both |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | Actelion Pharmaceuticals Japan Ltd. |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | Actelion Pharmaceuticals Japan Ltd. |
Secondary ID(s) | NCT03809650,JapicCTI-194627 |
Contact
Public contact | |
Name | |
Address | |
Telephone | |
exp.clinical.trial.jp@its.jnj.com | |
Affiliation | Actelion Pharmaceuticals Japan Ltd. |
Scientific contact | |
Name | |
Address | |
Telephone | |
exp.clinical.trial.jp@its.jnj.com | |
Affiliation |